Background. Perioperative administration of cefazolin reduces the incidence of perioperative infections. Intraoperative redosing of cefazolin is commonly given between 2 and 5 h after the initial dose. This study was undertaken to determine whether intraoperative continuous infusions of cefazolin achieve better probability of target attainment (PTA) and fractional target attainment (FTA) than intermittent dosing. Methods. Patients undergoing major surgery received cefazolin 2 g before surgical incision. They were subsequently randomized to receive either an intermittent bolus (2 g every 4 h) or continuous infusion (500 mg h
Administration of an appropriate antibiotic, such as cefazolin, before incision significantly reduces the risk of developing an SSI. 1 After the pre-incision dose of cefazolin, which is administered up to 60 min before surgery, re-dosing intervals vary between 2 and 5 h based on a combination of drug properties and patient-and surgery-specific factors. 3 Currently, re-dosing of perioperative cefazolin is recommended when the duration of surgery exceeds one-to-two drug half-lives or if there is excessive blood loss (>1500 ml). 4 Subtherapeutic plasma drug concentrations requiring modification of the re-dosing interval are also seen with rapid changes in the volume of distribution, such as during cardiopulmonary bypass, 5 burns, or with changes in renal function. 6 Cefazolin is a time-dependent antibiotic that demonstrates maximal efficacy when serum concentrations are above the minimal inhibitory concentration (MIC; ƒT>MIC). Generally, in vitro bacteriostatic and bactericidal activities for b-lactam antibiotics, such as cefazolin, are present when free plasma concentrations are maintained above the MIC for 35-40 and 60-70% of the dosing interval, respectively. 7 8 However, in critically ill and immunocompromised patients clinical outcomes appear to be improved if the ƒT>MIC for cephalosporins is 100% of the dosing interval. 9 For perioperative surgical prophylaxis, the goal is also to maintain free drug concentrations above ƒT>MIC for 90-100% of the dosing interval. 10 There are currently limited studies investigating the perioperative pharmacokinetics of cefazolin and when re-dosing should occur subsequent to the pre-incision dose. Furthermore, there are few data to describe whether use of a continuous infusion of cefazolin may increase the likelihood of maintaining effective concentrations throughout the surgical procedure.
In this randomized open-label study, we compared the population pharmacokinetics and the likely success of treatment of cefazolin administered by intermittent vs continuous infusion during major surgery. We hypothesized that continuous infusions of cefazolin (after a standard pre-incision dose) are more effective in achieving the a priori probability of target attainment (PTA) of 100% ƒT>MIC against at least 90% of bacterial isolates than an intermittent dosing regimen.
Methods
This was a prospective open-label observational randomized controlled pharmacokinetic trial. The study was approved by the University of Virginia Institutional Review Board (UVA HSR #17266) and was registered under Clinical Trial number: NCT02058979. Written consent was obtained before randomization. A CONSORT diagram is provided in the Supplementry material, Fig. S1 .
Patient selection and data collection
All patients undergoing major urological or multilevel spine surgery were screened. We recruited subjects between 18 and 80 yr of age whose weight was <120 kg with an arterial line. Exclusion criteria included patients with an allergy to b-lactams, pregnant females, creatinine clearance <30 ml min À1 , and those patients who received cefazolin within 72 h before surgery.
Anaesthesia management
Induction and maintenance of anaesthesia, fluid management, autologous and allogeneic transfusion, and administration of intraoperative analgesia were at the discretion of the attending anaesthestist.
Study protocol
Between 15 and 60 min before surgical incision, 2 g of cefazolin (2 g cefazolin diluted in 50 ml of 5% dextrose water; final concentration 40 mg ml À1 ) was administered i.v. during 5 min in both the intermittent bolus and continuous infusion groups, consistent with current Surgical Care Improvement Project (SCIP) guidelines.
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Randomization used a block design, with the stratification factor being the sex of the subject. The block sizes of both arms were five males and five females per arm. Patients were randomized to either an intermittent bolus or a continuous infusion group. The research staff performed the randomization.
In the intermittent bolus group, cefazolin 2 g was administered every 4 h until skin closure after the initial pre-incision.
In the continuous infusion group, a cefazolin infusion was started immediately after the 2 g pre-incision dose. The continuous infusion dose was prepared as described for the preincision dose. The infusion rate was set to deliver 500 mg h À1 (12.5 ml h À1 of the study drug) and was continued until skin closure. The University of Virginia Research Pharmacy supplied the study drug for both the intermittent bolus and continuous infusion groups. Postoperative cefazolin administration was at the discretion of the surgical team managing the patient and was consistent with institutional and national guidelines. Editor's key points
• Cefazolin is a first generation cephalosporin commonly used for perioperative surgical site infection prophylaxis.
• The time that the free fraction exceeds the minimal inhibitory concentration (fT>MIC) determines efficacy.
• The authors studied the probability of target concentration attainment with intermittent boluses and continuous infusions.
• Intraoperative infusions increased the achievement of target plasma concentrations even with lower infusion doses.
on ice and centrifuged within 60 min at 1309 g for 10 min. Plasma samples were then stored at À80 C until analysis.
Data collection
Data collected included demographic data (age, sex, weight, height, and BMI), ASA classification, type and duration of surgery, baseline renal function as determined by the calculated creatinine clearance, intraoperative urine output, blood loss, and total allogeneic and autologous transfusion.
Measurement of total and unbound cefazolin concentrations
Cefazolin concentrations in plasma were measured by a validated Ultra-high pressure liquid chromatography-tandem mass spectrometer (UHPLC-MS/MS) method from 1 to 500 lg ml
À1
(total cefazolin, Columbia, MD, USA) and from 0.1 to 500 lg ml
(unbound cefazolin, Columbia, MD, USA) on a Shimadzu Nexera UHPLC connected to a Shimadzu 8030þ triple quadrupole mass spectrometer. 12 Clinical samples were assayed alongside plasma calibrators and quality controls and met batch acceptance criteria (www.fda.gov/downloads/Drugs/Guidances/ ucm070107.pdf, accessed 25 July 2016).
Unbound cefazolin was measured at three time points only (T0þ5, T0þ30, and T0þ120 min). Measured unbound cefazolin concentrations were used to extrapolate the unbound cefazolin concentration for each of the total cefazolin measurements in the study cohort.
Population pharmacokinetic modelling
Population pharmacokinetic modelling was performed only on total plasma cefazolin concentrations whereby one-and twocompartment models were developed with the non-parametric adaptive grid (NPAG) algorithm within the freely available Pmetrics V R software package for R (Los Angeles, CA, USA). 13 14 Elimination from the central compartment and intercompartmental distribution into the peripheral compartment (two-compartment model) were modelled as first-order processes. Discrimination between different models used comparison of the À2 log likelihood (À2LL). A P-value of <0.05 was considered statistically significant.
Population pharmacokinetic covariate screening
Age, sex, body weight, BMI, ASA classification, measured creatinine clearance, urine output, allogeneic blood products, and perioperative fluid volumes were evaluated as clinically relevant and physiologically plausible covariates. Covariate selection was performed using a stepwise linear regression on all covariates and Bayesian posterior parameters. Potential covariates were separately entered into the model and statistically tested by use of the À2LL values. If inclusion of the covariate resulted in a statistically significant improvement in the À2LL values (P<0.05), improved the goodness-of-fit plots, or both then the covariate was retained in the final model.
Model diagnostics
Goodness of fit was assessed by linear regression, with an observed-predicted (both population-and individual-predicted concentrations) plot, coefficients of determination, and À2LL values. Predictive performance was based on mean prediction error (bias) and the mean bias-adjusted squared prediction error (imprecision) of the population and individual prediction models. The internal validity of the population pharmacokinetic model was assessed by the bootstrap resampling method (n¼1000) and normalized prediction distribution errors (NPDEs). 15 Using the visual predictive check (VPC) method, parameters obtained from the bootstrap method were plotted with the observed concentrations. The NPDE plots were checked for normal distribution characteristics and trends in the data errors.
Probability of target attainment
Monte Carlo simulations (n¼1000) were used using Pmetrics to determine the PTA of achieving the pharmacokinetic/pharmacodynamic (PK/PD) target of 100% ƒT>MIC for varying MICs (0.064-64 mg litre
À1
) during the first 4 h of surgery. A fixed 21% unbound value of cefazolin was used for the simulations based on the 90th percentile of unbound fraction of cefazolin (21%) from the samples obtained 120 min post-initial dosing, a value considered as the 'worst-case scenario' for the unbound fraction of cefazolin in these patients. Intermittent i.v. doses of 2 g 4-hourly, 2 g 3-hourly, 2g 2-hourly, and continuous infusion of 0.5, 1, and 2 g during 4 h after the administration of a 2 g loading dose were simulated. Three different levels of renal function (creatinine clearances of 50, 80, and 120 ml min
) and three different total body weights (60, 80, and 100 kg) were tested that reflected the broad distribution of values observed in this patient population. Three different durations of surgery (3, 4, and 5 h) were also simulated.
Fractional target attainment calculation
The fractional target attainment (FTA) identifies the likely success of treatment by comparing the pharmacodynamic exposure (PTA) of cefazolin against an MIC distribution. A dosing regimen was considered successful if the a priori PTA of 100% ƒT>MIC against at least 90% of isolates was achieved. The MIC distribution of pathogens commonly implicated in SSIs after orthopaedic, abdominal, or urological surgery; meticillin-susceptible Staphylococcus aureus, Staphylococcus epidermidis and Escherichia coli were obtained from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) database (available at www.eucast.org; accessed 10 April 2016) and used to determine the FTA.
Statistical analysis
Summary perioperative data are reported as the mean (SD) or median (range) based on whether they were normally distributed. Student's unpaired t-test or the Mann-Whitney U-test was used to assess for significance between the groups, and statistical significance was defined for values of P<0.05.
Results
A total of 20 patients were enrolled (10 patients in each arm). Demographic and intraoperative data are presented in Table 1 . No significant differences in baseline characteristics, including creatinine clearance, intraoperative blood loss, blood transfusions, and crystalloid and albumin administration, were observed between the two groups. The mean (SD) observed concentration-time profile of the 318 total cefazolin and 60 unbound cefazolin concentrations in the bolus and continuous infusion groups are shown in Fig. 1 
Pharmacokinetic model
A two-compartment linear model best described the time course of the total plasma concentrations (Supplementary  material, Fig. S2 ). This model included zero-order input of drug into the central compartment. The only covariate that improved the fit of the model was, for cefazolin clearance, creatinine clearance normalized to the mean population value, 80 ml min À1 , and for cefazolin central volume of distribution, total body weight normalized to the mean population value, 80 kg (to the power of 0.75; P<0.05). After including creatinine clearance and total body weight, the À2LL values decreased (À9 DÀ2LL, P¼0.34 and À52 DÀ2LL P¼0.32, respectively) and the overall goodness of fit improved. For these reasons, creatinine clearance and total body weight were retained in the final covariate model. No covariate effect on the intercompartmental clearances was found. The final covariate model was described as follows:
Cefazolin clearance¼TVCL*(CrCl/80) Cefazolin central volume¼TVVc*(WT/80)**0.75
Where TVCL is the typical value of cefazolin clearance, CrCl is creatinine clearance in millilitres per minute, TVVc is the typical value of cefazolin central volume of distribution, and WT is total body weight in kilograms.
The mean (SD) population pharmacokinetic parameter estimates from the final covariate two-compartment model are described in the Supplemental material, Table S1 . The diagnostic plots to confirm the goodness of fit of the model were considered acceptable (Supplemental material, Figs S3A and B and S4). The final covariate model was then used for dosing simulations.
Dosing simulations
Simulated unbound concentrations of cefazolin were determined by using the 90th percentile of the unbound fraction of cefazolin (21%) from the samples obtained 120 min post-initial dosing, a value considered as the 'worst-case scenario' for the unbound fraction of cefazolin in these patients. The Monte Carlo simulations and PTAs of 100% ƒT>MIC for various cefazolin doses for a standard patient with a creatinine clearance of 80 ml min À1 and a total body weight of 80 kg are described in 
Fractional target attainment
The FTAs for the range of cefazolin doses (intermittent and continuous doses), total body weights, and creatinine clearances against susceptible MIC distributions for S. aureus, S. Epidermidis, and E. coli are shown in Table 2 .
Discussion
Our study demonstrates that continuous infusions of cefazolin consistently achieve better FTAs in >90% of isolates for S. aureus (meticillin susceptible) and E. coli across a range of body weights and creatinine clearances during surgery. Improved PK/PD profiles are evident even when lower dose continuous cefazolin infusions are used (500 and 1000 mg during 4 h) compared with standard intermittent therapy (2 g every 4 h). Intermittent dosing that achieves comparable FTA to continuous infusions requires more frequent re-dosing (every 2 or 3 h).
The FTA for S. epidermidis was generally below the a priori target of 90% in both the intermittent and continuous groups. However, in the continuous infusion group (1000 and 2000 mg during 4 h), reduced creatinine clearance is associated with a higher FTA. The likely portal of entry for S. epidermidis is thought to be direct inoculation of skin commensals during surgery. 16 Furthermore, the ability of S. epidermidis to generate biofilms makes effective penetration and treatment more difficult. 17 Therefore, prevention of infections by this potential pathogen at the time of surgery is important. Our data indicate that continuous infusions of cefazolin result in better FTA for S. epidermidis (79-98% for 1000 mg during 4 h and 83-100% for 2000 mg for 4 h) compared with 2 g every 3 h (75-84%) and 2 g every 2 h (80-86%) across a varying range of creatinine clearances and body weights. However, our data suggest that an agent other than cefazolin should be considered when S. epidermidis is the suspected causative pathogen. The FTA data presented above can identify patients at risk of suboptimal PK/PD (high creatinine clearance and increased body weight) and assist the anaesthesia provider with appropriate dosing, particularly when the risk of perioperative SSIs is high.
Based on our findings, after an appropriate weight-based loading dose of cefazolin, optimal PK/PD profiles and FTA are best achieved with continuous infusions. These effects are still evident when lower continuous infusion rates (500 and 1000 mg during 4 h) are used compared with intermittent dosing.
A two-compartment linear model with body weight and creatinine clearance as covariates best described the time course of the total plasma cefazolin concentrations in our cohort. The interaction of baseline creatinine clearance, body weight, and choice of dosing regimen has a significant impact on an a priori defined FTA (Table 2) . Standard intermittent cefazolin dosing of 2 g every 4 h in patients with an elevated creatinine clearance and body weight can result in suboptimal FTA for all studied pathogens and can potentially predispose to the development of SSI. Toma and colleagues 7 describe suboptimal tissue penetration and drug concentrations of another cephalosporin, cefoxitin, in morbidly obese patients undergoing abdominal surgery even when the dose is doubled, whereas Isla and colleagues 6 showed that with a creatinine clearance >60 ml min À1 , re-dosing for cefoxitin is required every 1.5 h and even more frequently (every hour) when the creatinine clearance is >100 ml min À1 . These findings are consistent with our FTA data of unbound concentrations that analysed varying body weights and creatinine clearances. Based on the high prevalence of elevated body weight in the USA {overall age-adjusted prevalence For cardiac surgery requiring cardiopulmonary bypass, better PK/PD targets are achieved with continuous cefazolin infusions. 18 Adembri and colleagues 18 reported that ƒT>MIC 90% was achieved in 90% of patients on continuous infusions vs 30% in the intermittent group. However, no PTA modelling for different covariates and FTA data were reported in their study. The focus on improving the intraoperative PK/PD of dosing for b-lactams is yet to be supported by large clinical outcome trials. It is important to note that other studies of b-lactams for treatment of severe infections investigating the utility of continuous infusions focus primarily on the critically ill intensive care unit patient and have failed to demonstrate improved outcomes consistently in these patients. 19 20 Clinical trials that did demonstrate benefits with continuous infusions are confined to specific subpopulations, namely critically ill patients with infections caused by pathogens with elevated MICs. 8 21 The benefits of continuous b-lactam infusions in this subgroup of patients, where altered volumes of distribution and elevated creatinine clearances are frequently encountered, may be attributable to better tissue penetration and tissue drug concentrations.
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As remarked above, currently there are no data on the effects of continuous intraoperative antibiotic infusions on postoperative outcomes. However, the cost and morbidity associated with SSIs are significant, and optimizing PK/PD goals is an important first step to mitigate these risks. Our data, the first to use an a priori PTA and FTA goal, highlight the importance of weight, creatinine clearance, and dosing regimen for achieving optimal targets for three commonly encountered nosocomial pathogens. These factors should be considered when post-incisional antibiotic administration is required.
There are several limitations of this study that need to be highlighted. The PTA was defined a priori (100% ƒT>MIC), and changing this variable would have a significant impact on the FTA data. We decided a priori on a 100% ƒT>MIC based on PK/PD concepts for surgical prophylaxis as have been used by other studies. 10 Albumin concentrations were not measured and potentially would play an important role in certain subgroups (e.g. trauma). 23 Tissue and interstitial concentrations of cefazolin, which might more accurately reflect target site concentrations, were not measured. Although our group has previously shown that the penetration of unbound drug from plasma to interstitial fluid is significant at approximately 74-85% (34-106%), penetration targets for specific organs (e.g. muscle, bladder tissue, or bone) are not known. 22 23 Finally, this study was a pharmacokinetic analysis, and no postoperative clinical outcomes, such as SSIs, were recorded. Future prospective randomized studies using intermittent vs continuous cefazolin infusions during surgery to determine their impact on SSIs are needed. 
Conclusion
Based on plasma concentrations of cefazolin, our study demonstrates that intraoperative continuous infusions provide better FTA with lower infusion doses. Renal function and body weight are important covariates for optimizing the doses and method of delivery of cefazolin required to achieve ideal PK/PD targets.
